Lunai Bioworks Inc. (LNAI)
NASDAQ: LNAI · Real-Time Price · USD
0.9600
+0.0498 (5.47%)
At close: Jan 9, 2026, 4:00 PM EST
0.9408
-0.0192 (-2.00%)
After-hours: Jan 9, 2026, 7:51 PM EST
Lunai Bioworks Employees
Lunai Bioworks had 29 employees as of June 30, 2025. The number of employees increased by 4 or 16.00% compared to the previous year.
Employees
29
Change (1Y)
4
Growth (1Y)
16.00%
Revenue / Employee
n/a
Profits / Employee
-$4,516,429
Market Cap
22.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 29 | 4 | 16.00% |
| Jun 30, 2024 | 25 | 13 | 108.33% |
| Jun 30, 2023 | 12 | -10 | -45.45% |
| Jun 30, 2022 | 22 | 11 | 100.00% |
| Jun 30, 2021 | 11 | 1 | 10.00% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LNAI News
- 22 days ago - Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - PRNewsWire
- 4 weeks ago - Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - PRNewsWire
- 6 weeks ago - Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - PRNewsWire
- 2 months ago - Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy - PRNewsWire
- 2 months ago - Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds - Accesswire
- 3 months ago - Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics - Accesswire
- 3 months ago - Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement - Accesswire
- 3 months ago - Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline - Accesswire